Anesiva (ANSV) rallied in pre-market trading, after getting FDA approval for its sNDA to expand indication for Zingo to treat pain associated with blood draws in adults.
The stock was up 27 cents around 9:20 am ET, rising to 95 cents. If pre-market gains hold, the stock will open at its highest level since mid-December.
Friday, Anesiva said it received an approval from U.S. Food and Drug Administration or FDA for its supplemental New Drug Application or sNDA to expand the indication for Zingo to treat the pain associated with blood draws to include adults.
Zingo powder intradermal injection system was previously approved to treat the pain associated with peripheral IV insertions and blood draws in children three to 18 years of age. The notification was received according to PDUFA deadlines.
For comments and feedback: editorial@rttnews.com